2014

Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021

NEW YORK, July 13, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021

http://www.reportlinker.com/p0572968/Pharmaceutical-Wholesale-and-Distribution-Industry-World-Outlook-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Wholesali

How will events this decade affect those activities?

How will the pharma wholesale and distribution industry perform from 2011 onwards? Our new report shows you that industry and market's revenue potential from 2011 to 2021.

There, you will assess the trends and opportunities shaping the pharmaceutical distribution chain. We aim to save you time and aid your decisions through our research, analysis and discussions. 

Our report shows you revenue prospects for pharmaceutical wholesale and distribution activities at total world, company and national levels. 

We forecast revenues of McKesson (US), Cardinal Health (US), AmerisourceBergen (US), The Phoenix Group (Europe), Celesio (Europe), Alfresa Holdings (Japan), Medipal (Japan), Alliance Boots (Europe) and Suzuken (Japan). You will discover their prospects to 2021.

What effects will healthcare budget cuts have on pharmaceutical wholesalers? Which national markets will provide the best opportunities from 2011 to 2021? How common will direct-to-pharmacy distribution become? Our work provides answers you need.

We help you to assess the pharma wholesale and distribution industry's strengths, weaknesses, trends and revenue opportunities to 2021. You will see where the industry and market are heading. 

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now. 

Industry and market analysis to help your work - so you won't be left behind

Our report gives you revenue forecasts, growth rates and market shares. We also provide a SWOT/STEP review, analysis of companies and external opinions from our industry survey. 

We include 117 tables and charts and two research interviews (shown in the accompanying lists). Our study helps you to understand pharma wholesaling and distribution this decade.

Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:

• You will receive hard data for the pharmaceutical wholesale and distribution industry and market from 2009 to 2021

• You will discover revenue forecasting for the overall world market from 2011 to 2021

• You will assess leading companies in the pharma distribution chain, discovering their activities, potential revenue values and commercial outlooks to 2021

• You will find revenue predictions for leading geographical markets to 2021 (US, Japan, China, Germany, France, UK, Spain, Italy, Brazil and Russia)

• You will investigate competition and opportunities that will influence revenues

• You will see what will stimulate and restrain the industry and market

• You will view opinion from our survey, including full interview transcripts.

That mix of quantitative and qualitative market analysis sets our report apart. Our independent analysis helps you to stay ahead in commercial knowledge.

Order our report now to gain industry and market information you need

Our report can benefit everybody interested in pharmaceutical wholesaling and distribution. We give predictions and answers you need. Don't miss out - please order our report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs

Table of Contents

1. Executive Summary

1.1 Overview of the Study

1.2 Chapter Breakdown

1.3 Research and Analysis Methods

2. Introduction to the Industry and Market

2.1 The Role of Pharmaceutical Wholesalers

2.1.1 Full-Line Wholesalers (FLWs)

2.1.2 Short-Line Wholesalers (SLWs)

2.2 The Chain of Distribution

2.2.1 Secondary Wholesalers

2.2.2 Direct-to-Pharmacy

2.2.3 Pharmacy Benefit Managers

2.3 Generating Revenue and Profit

2.3.1 Forward Buying

2.3.2 Fee-for-Service

2.3.2.1 Inventory Management Agreements

2.3.3 Discounts

2.3.4 Reimbursement and Wholesalers

2.3.5 Clawback

2.3.6 Parallel Trade

3. The World Pharmaceutical Wholesale and Distribution Market 2011-2021

3.1 The World Market in 2009

3.2 World Market Forecast 2011-2021

3.3 The US

3.3.1 An Increase in Fee-for-Service Activity

3.3.2 US Market Forecast 2011-2021

3.4 Europe

3.4.1 Differences between the US and Europe

3.4.1.1 State-Funded Healthcare and Reimbursement

3.4.2 European Market Forecast 2011-2021

3.4.3 Germany

3.4.3.1 Healthcare Reform

3.4.3.2 Market Forecast 2011-2021

3.4.4 France

3.4.4.1 Market Forecast 2011-2021

3.4.5 Spain

3.4.5.1 Market Forecast 2011-2021

3.4.6 The UK

3.4.6.1 Price Cuts 2009-2010

3.4.6.2 Market Forecast 2011-2021

3.4.7 Italy

3.4.7.1 Market Forecast 2011-2021

3.5 Japan

3.5.1 Drug Pricing and Performance Fees

3.5.2 Market Forecast 2011-2021

3.6 China

3.6.1 Leading Companies 2009-2010

3.6.2 Recent Market Developments

3.6.3 Market Forecast 2011-2021

3.7 Brazil

3.7.1 Leading Companies 2009-2010

3.7.2 Market Forecast 2011-2021

3.8 Russia

3.8.1 Market Trends

3.8.2 Market Forecast 2011-2021

3.9 Regional Market Shares 2011-2021

4. Leading Wholesalers in the Global Market 2011-2021

4.1 Revenue vs. Profit

4.1.1 Profit Margins 2009

4.2 Leading Companies Market Forecast 2011-2021

4.3 McKesson

4.3.1 Recent Performance

4.3.2 Future Strategies

4.3.3 Revenue Forecast 2011-2021

4.4 Cardinal Health

4.4.1 Segment Reorganisation

4.4.2 Recent Performance

4.4.3 Future Strategies

4.4.4 Revenue Forecast 2011-2021

4.5 AmerisourceBergen

4.5.1 Recent Performance

4.5.2 Future Strategies

4.5.3 Revenue Forecast 2011-2021

4.6 The Phoenix Group

4.6.1 Recent Performance

4.6.2 The Tamro Group 2009-2010

4.6.3 Future Strategies

4.6.4 Revenue Forecast 2011-2021

4.7 Celesio

4.7.1 Recent Performance

4.7.2 Future Strategies

4.7.3 Revenue Forecast 2011-2021

4.8 Alfresa Holdings

4.8.1 Recent Performance

4.8.2 Future Strategies

4.8.3 Revenue Forecast 2011-2021

4.9 Medipal

4.9.1 Recent Performance

4.9.2 Future Strategies

4.9.3 Revenue Forecast 2011-2021

4.10 Alliance Boots

4.10.1 Recent Performance

4.10.2 Future Strategies

4.10.3 Revenue Forecast 2011-2021

4.11 Suzuken

4.11.1 Recent Performance

4.11.2 Future Strategies

4.11.3 Revenue Forecast 2011-2021

5. Qualitative Analysis of the Market 2011-2021

5.1 SWOT Chart for the Pharmaceutical Wholesale and Distribution Market 2011-2021

5.2 Strengths

5.2.1 Large Companies Dominate the Market

5.2.2 Wholesalers Do More than Deliver Drugs

5.2.2.1 Pre-Wholesaling

5.3 Weaknesses

5.3.1 Counterfeiting

5.3.2 Low Margins

5.4 Opportunities

5.4.1 Increased Demand for Pharmaceuticals

5.4.2 Generics

5.4.3 Globalisation

5.5 Threats

5.5.1 Direct-to-Pharmacy (DTP)

5.5.1.1 DTP in Europe

5.5.1.2 The UK

5.5.1.3 Poland

5.5.1.4 DTP in Australia

5.5.1.5 Further Expansion

5.5.2 Healthcare Budget Cuts

5.5.3 Diversion and Re-importation

5.5.4 Supermarket Pharmacies

5.5.4.1 Case Study: Walmart

6. Pharmaceutical Wholesale Industry Trends 2011-2021

6.1 Combating Counterfeit Medicines

6.1.1 The US and E-Pedigree

6.1.2 European Pedigree Legislation

6.1.3 Anti-Counterfeiting Strategies in Other Markets

6.1.4 Issues in Serialisation for Wholesalers

6.2 Growth in Specialty Pharmaceuticals

6.3 Industry Consolidation

6.4 Chain Pharmacies and Vertical Integration

7. Opinions from Our Survey

7.1 Professor David Taylor, Professor of Pharmaceutical and Public Health Policy, University of London

7.1.1 The Purpose of DTP

7.1.2 The Impact of DTP on Pharmacies

7.1.3 Changes to Drug Pricing in the UK

7.1.4 DTP and the Patient

7.1.5 Wholesale Trends Across Europe

7.2 Dr Heinz Kobelt, Secretary-General, European Association of Euro-Pharmaceutical Companies (EAEPC)

7.2.1 Benefits of Parallel Trade

7.2.2 Generics and Parallel Trade

7.2.3 Parallel Traders Combating Counterfeiting

7.2.4 The DTP Model

8. Conclusions

8.1 There Will Be Steady Growth in Developed Markets

8.1.1 Generics Will Threaten Revenues

8.1.2 Manufacturers Will Deliver Direct More Regularly

8.1.3 There Will Be Greater Demand for Specialty Medicines

8.2 Growth Will Be Faster in Emerging Markets

8.2.1 Consolidation Will Drive Growth

8.3 Anti-Counterfeiting Demands Will Add to Wholesalers' Costs

List of Tables

Table 2.1 Prevalence of the DTP Model in the UK, 2011

Table 3.1 Global Pharmaceutical Wholesale and Distribution Market by Country, 2009 

Table 3.2 Global Pharmaceutical Wholesale Market Forecast, 2009-2021

Table 3.3 Global Market Drivers and Restraints, 2011-2021

Table 3.4 US Pharmaceutical Wholesale and Distribution Market by Company, 2009

Table 3.5 US Market Drivers and Restraints, 2011-2021

Table 3.6 European Pharmaceutical Wholesale and Distribution Market by Country, 2009

Table 3.7 How Price Controls Vary Across Europe, 2010

Table 3.8 European Market Drivers and Restraints, 2011-2021

Table 3.9 European Pharmaceutical Wholesale Market Forecast, 2009-2021

Table 3.10 German Market Drivers and Restraints, 2011-2021

Table 3.11 French Market Drivers and Restraints, 2011-2021

Table 3.12 Spanish Market Drivers and Restraints, 2011-2021

Table 3.13 UK Pharmaceutical Wholesale and Distribution Market by Company, 2009

Table 3.14 UK Market Drivers and Restraints, 2011-2021

Table 3.15 Italian Market Drivers and Restraints, 2011-2021

Table 3.16 Japanese Points of Delivery, 2011

Table 3.17 Japanese Pharmaceutical Wholesale and Distribution Market, 2009

Table 3.18 Global Population Aged Over 65, 2009-2025

Table 3.19 Japanese Market Drivers and Restraints, 2011-2021

Table 3.20 Chinese Market Drivers and Restraints, 2011-2021

Table 3.21 Brazilian Market Drivers and Restraints, 2011-2021

Table 3.22 Russian Pharmaceutical Wholesale and Distribution Market, 2009

Table 3.23 Russian Market Drivers and Restraints, 2011-2021

Table 4.1 Leading Companies in the Market, 2009

Table 4.2 Company Year End Revenues, 2009

Table 4.3 Profit Margins Reported by Leading Companies, 2009

Table 4.4 Market Leaders: Drivers and Restraints, 2011-2021

Table 4.5 Pharmaceutical Wholesale Market Leaders: Forecast, 2009-2021

Table 4.6 McKesson Pharmaceutical Wholesale Revenue by Country, 2009 

Table 4.7 McKesson Pharmaceutical Wholesale Revenue and Gross Profit by Quarter, 2009

Table 4.8 McKesson Wholesale Revenue Forecast, 2009-2021

Table 4.9 Cardinal Health's Bulk and Non-bulk Orders, 2009-2010

Table 4.10 Cardinal Health Wholesale Revenue Forecast, 2009-2021

Table 4.11 AmerisourceBergen Pharmaceutical Distribution Revenue and Gross Profit by Quarter, 2009 

Table 4.12 AmerisourceBergen Pharmaceutical Distribution Revenue and Gross Profit, Q1-Q3 2010

Table 4.13 AmerisourceBergen Wholesale Revenue Forecast, 2009-2021

Table 4.14 The Phoenix Group Wholesale Subsidiaries, 2010

Table 4.15 The Phoenix Group Revenue and Gross Profit, February-October 2009-2010

Table 4.16 Tamro Group Revenue, 2009-2010

Table 4.17 The Phoenix Group Wholesale Revenue Forecast, 2009-2021

Table 4.18 Celesio Wholesale Subsidiaries, 2010

Table 4.19 Celesio Wholesale Revenue by Country, 2009

Table 4.20 Celesio Wholesale Revenue Forecast, 2009-2021

Table 4.21 Alfresa Wholesale Subsidiaries, 2010

Table 4.22 Alfresa Wholesale Revenue and Operating Income by Quarter, 2009

Table 4.23 Alfresa Wholesale Revenue Forecast, 2009-2021

Table 4.24 Medipal Wholesale Revenue and Operating Income by Quarter, 2009

Table 4.25 Medipal Wholesale Revenue and Operating Income, Q1-Q3 2010 

Table 4.26 Medipal Wholesale Revenue Forecast, 2009-2021

Table 4.27 Alliance Boots Wholesale Revenue by Country, 2009

Table 4.28 Alliance Boots Wholesale Revenue Forecast, 2009-2021

Table 4.29 Suzuken Wholesale Revenue and Operating Income by Quarter, 2009

Table 4.30 Suzuken Wholesale Revenue and Operating Income, Q1-Q3 2010 

Table 4.31 Suzuken Wholesale Revenue Forecast, 2009-2021

Table 5.1 SWOT Chart for the Pharmaceutical Wholesale and Distribution Market, 2011-2021

Table 5.2 Revenues for Leading Wholesalers and Manufacturers, 2009

Table 5.3 Regional Split of Counterfeiting Incidents, 2009

Table 5.4 Global Recorded Incidents of Counterfeit Medicines, 2002-2009

Table 5.5 Strengths and Weaknesses of the DTP Model

Table 8.1 Global Pharmaceutical Wholesale Market Shares by Country, 2009, 2015 and 2021

Table 8.2 US Patent Expiries for Leading Small Molecule Drugs, 2010-2012

List of Figures

Figure 2.1 Traditional Routes of Drug Distribution, 2011

Figure 2.2 CVS Caremark Revenue by Segment, 2009 

Figure 3.1 Global Pharmaceutical Wholesale and Distribution Market by Country, 2009

Figure 3.2 Global Pharmaceutical Wholesale Market Forecast, 2009-2021

Figure 3.3 US Pharmaceutical Wholesale and Distribution Market by Company, 2009

Figure 3.4 US Pharmaceutical Wholesale Market Forecast, 2009-2021

Figure 3.5 European Pharmaceutical Wholesale and Distribution Market by Country, 2009

Figure 3.6 European Pharmaceutical Wholesale Market Forecast, 2009-2021

Figure 3.7 German Pharmaceutical Wholesale Market Forecast, 2009-2021

Figure 3.8 French Pharmaceutical Wholesale Market Forecast, 2009-2021

Figure 3.9 Spanish Pharmaceutical Wholesale Market Forecast, 2009-2021

Figure 3.10 UK Pharmaceutical Wholesale and Distribution Market by Company, 2009

Figure 3.11 UK Pharmaceutical Wholesale Market Forecast, 2009-2021

Figure 3.12 Italian Pharmaceutical Wholesale Market Forecast, 2009-2021

Figure 3.13 Japanese Points of Delivery, 2011

Figure 3.14 Japanese Pharmaceutical Wholesale and Distribution Market, 2009

Figure 3.15 Changes to Japanese Drug Pricing, 2010

Figure 3.16 Aging Global Population, 2009-2025

Figure 3.17 Japanese Pharmaceutical Wholesale Market Forecast, 2009-2021

Figure 3.18 Chinese Pharmaceutical Wholesale Market Forecast, 2009-2021

Figure 3.19 Brazilian Pharmaceutical Wholesale Market Forecast, 2009-2021

Figure 3.20 Russian Pharmaceutical Wholesale and Distribution Market, 2009

Figure 3.21 Russian Pharmaceutical Wholesale Market Forecast, 2009-2021

Figure 3.22 Global Pharmaceutical Wholesale and Distribution Market by Country, 2015

Figure 3.23 Global Pharmaceutical Wholesale and Distribution Market by Country, 2021

Figure 4.1 Leading Companies in the Market, 2009

Figure 4.2 Pharmaceutical Wholesale Market Leaders: Forecast, 2009-2021

Figure 4.3 McKesson Pharmaceutical Wholesale Revenue by Country, 2009

Figure 4.4 McKesson Pharmaceutical Wholesale Revenue and Gross Profit by Quarter, 2009

Figure 4.5 McKesson Wholesale Revenue Forecast, 2009-2021

Figure 4.6 Cardinal Health Pharmaceutical Revenue by Company, FY 2009-2010

Figure 4.7 Cardinal Health's Bulk and Non-bulk Orders, FY 2009-2010

Figure 4.8 Cardinal Health Wholesale Revenue Forecast, 2009-2021

Figure 4.9 AmerisourceBergen Pharmaceutical Distribution Revenue by Quarter, 2009

Figure 4.10 AmerisourceBergen Wholesale Revenue Forecast, 2009-2021

Figure 4.11 The Phoenix Group Wholesale Revenue, February-October 2009-2010

Figure 4.12 Tamro Group Revenue, 2009-2010

Figure 4.13 The Phoenix Group Wholesale Revenue Forecast, 2009-2021

Figure 4.14 Celesio Wholesale Revenue by Country, 2009

Figure 4.15 Celesio Wholesale Revenue Forecast, 2009-2021

Figure 4.16 Alfresa Wholesale Operating Income Margin by Quarter, 2009

Figure 4.17 Alfresa Wholesale Revenue Forecast, 2009-2021

Figure 4.18 Medipal Wholesale Revenue by Quarter, 2009

Figure 4.19 Medipal Wholesale Operating Income Margin, Q1-Q3 2009-2010

Figure 4.20 Medipal Wholesale Revenue Forecast, 2009-2021

Figure 4.21 Alliance Boots Wholesale Revenue by Country, 2009

Figure 4.22 Alliance Boots Wholesale Revenue Forecast, 2009-2021

Figure 4.23 Suzuken Wholesale Revenue by Quarter, 2009

Figure 4.24 Suzuken Wholesale Operating Income Margin, Q1-Q3 2010

Figure 4.25 Suzuken Wholesale Revenue Forecast, 2009-2021

Figure 5.1 Revenues for Leading Wholesalers and Manufacturers, 2009

Figure 5.2 Regional Split of Counterfeiting Incidents, 2009

Figure 5.3 Global Recorded Incidents of Counterfeit Medicines, 2002-2009

Figure 5.4 Comparison of the Wholesaler and Direct-to-Pharmacy Routes

Figure 6.1 Anti-Counterfeiting Strategies in the US and Europe, 2011

Companies Listed

Acofarma (Asociación Cooperativas Farmacéuticas) [Spain]

Alfresa Holdings and its subsidiaries:

Alfresa 

Alfresa Medical Service 

Alfresa Nikken Sangyo

Ando Co

CS Yakuhin Co

Kowa Pharmaceuticals Co

Meisho Co

Odashima

Ryuyaku Co

Seiwa Sangyo Co

Shikoku Alfresa 

Alliance Boots and its subsidiaries:

Alliance Healthcare

Alloga

Almus Pharmaceuticals

Andreae-Noris Zahn (ANZAG) [Germany]

Cordia Healthcare

Galenica

Hedef Alliance Holding

HydraPharm [Algeria]

Megapharm [Germany]

UCP [Egypt]

AmerisourceBergen and its subsidiaries:

American Health Packaging

Anderson Packaging

Brecon Pharmaceuticals

Astellas Pharma

AstraZeneca

Athos Farma

Australian Pharmaceutical Industries

Barr Pharmaceuticals (now part of Teva Pharmaceuticals)

Bayer 

Bristol-Myers Squibb

British Association of Pharmaceutical Wholesalers (BAPW)

Bundesverband des Pharmazeutischen Grosshandel (PHAGRO) [Germany]

Cardinal Health and its subsidiaries:

Kinray

MediCap Pharmacy

Medicine Shoppe International

Zuellig Pharma China (Yong Yu)

CareFusion

Celesio and its subsidiaries:

AAH Pharmaceuticals [UK]

Admenta Italia [Italy]

Cahill May Roberts [Ireland]

Evolution Homecare [UK]

GEHE [Germany]

GEHE Pharma Praha [Czech Republic]

Herba Chemosan [Austria]

Inten [Germany]

Kemofarmacija [Slovenia]

Laboratoria Flandria [Belgium]

Norsk Medisinaldepot [Norway]

OCP [France/Portugal]

Panpharma [Brazil]

Pharma Belgium [Belgium]

Pharmactiv [France]

Tjellesen Max Jenne [Denmark]

Vitapharm [Slovenia]

Center for Medicine in the Public Interest [US]

CERP France (CERP Bretagne Nord, CERP Rhin Rhone Mediterranee and CERP Rouen)

Chambre Syndicale de la Répartition Pharmaceutique (CSRP) [France]

China Health Systems

China National Pharmaceutical Group (Sinopharm)

Cofares Hefame (formerly Cofares and Hefame)

CVS Caremark (formerly CVS and Caremark Rx)

Department of Health [UK]

Eli Lilly

European Association of Euro-Pharmaceutical Companies (EAEPC)

European Federation of Pharmaceutical Industries and Associations (EFPIA)

GlaxoSmithKline (GSK)

Guangzhou Pharmaceuticals 

Healthcare Distribution Management Association (HDMA) [US]

Hubei Kyoso Pharmaceutical (a Toho and Jointown joint venture)

Humana

Johnson & Johnson (J&J)

Japanese Pharmaceutical Wholesalers Association (JPWA)

Jointown Pharmaceutical Group

Katren

KL Holding

Kohlberg Kravis Roberts & Co (KKR)

McKesson and its subsidiaries:

Nadro

Oncology Therapeutics Network

Parata Systems

US Oncology

Medco Health Solutions

Medipal and its subsidiaries:

Atol Co

Chiyaku Co

Everlth Co

Izutsu Pharmaceutical Co

Kobashou Co

Kuraya Sanseido (now Mediceo)

Heisei Yakuhin Co

Nakagawa Seikodo Co

Sinopharm Medicine Holding Beijing Huahong

Ushioda Sagokudo Yakuhin Co

Ministry of Commerce [China]

Mitsubishi 

Napp Pharmaceutical Group

National Association of Boards of Pharmacy (NABP) [US]

National Health Service (NHS) [UK]

Novartis

Novo Nordisk

Pfizer

Pharmaceutical Security Institute (PSI) [US]

Polish Pharmaceutical Chamber

Polska Grupa Farmaceutyczna

Profarma

Prosper

Protek

ratiopharm

Rite-Aid

Roche

Rosta Pharmaceutical Group

Sanacorp

sanofi-aventis

Shanghai Pharmaceutical Group

SIA International

Sigma Pharmaceuticals

Sincamesp [Brazil]

State Food and Drug Administration (SFDA) [China]

Suzuken and its subsidiaries:

Astis Co

Jingu Yakuhin Co

Nakano Yakuhin Co

Sanki

Shanghai Suzuken Huzhong Pharmaceutical

Shoyaku Co

Suzuken Iwate Co

Suzuken Okinawa Yakuhin Co

Target

Teva Pharmaceuticals

The Phoenix Group and its subsidiaries:

Amedis-UE [Switzerland]

Apokjeden Group [Norway]

Brocacef Holding [The Netherlands]

Gruppo Comifar [Italy]

Libra [Bulgaria]

Nomeco [Denmark]

Numark [UK]

Phoenix Arzeiwarengro?handlung [Austria]

Phoenix Farmacija [Croatia]

Phoenix Lékárensky [Czech Republic]

Phoenix Healthcare Distribution [UK]

Phoenix Pharma [France/Hungary/Serbia]

Phoenix Pharma Polska [Poland]

Phoenix Pharmahandel [Germany]

Phoenix Zdravotnícke zasobovanie [Slovakia]

Rowlands [UK]

Tamro [Sweden]

SIA Tamro [Latvia]

Tamro Suomi [Finland]

Tamro Eesti [Estonia]

UAB Tamro [Lithuania]

Toho Holdings

Torfarm

United Nations (UN)

Walgreens

Walmart

Wyeth Pharmaceuticals (now part of Pfizer)

To order this report:

Wholesaling Industry: Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021

Wholesaling Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.